| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/29/2001 | US6238859 Virus protein antigens of the JC virus |
| 05/29/2001 | US6238706 Method of stimulating growth in aquatic animals using growth hormones |
| 05/29/2001 | US6238689 Intestinal absorption of nicotine to treat nicotine responsive conditions |
| 05/29/2001 | US6238669 Proteins encoded by chicken anemia virus DNA and diagnostic kits and vaccines employing said proteins |
| 05/29/2001 | US6238666 Polypeptide |
| 05/29/2001 | US6238664 Process for stabilizing proteins |
| 05/29/2001 | US6238662 The use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from alpha-l-iduronidase deficiency. |
| 05/29/2001 | US6238661 Use of bacterial phage associated lysing enzymes for treating various illnesses |
| 05/29/2001 | US6238659 Administering a compound influencing the cellular redox state which is a pyrrolidine dithiocarbamate or a derivative and a cytokine |
| 05/29/2001 | CA2225450C Interleukin-1 receptor-associated protein kinase and assays |
| 05/29/2001 | CA2214410C Peptide and a method of obtaining it |
| 05/29/2001 | CA2171638C The semaphorin gene family |
| 05/29/2001 | CA2065292C Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction |
| 05/29/2001 | CA2064915C Tumour necrosis factor binding ligands |
| 05/29/2001 | CA2034881C Factor x-laci hybrid protein |
| 05/29/2001 | CA2031803C Improvements in or relating to glycopeptide deriveratives |
| 05/25/2001 | WO2001036979A2 Placental human neurokinin b precursor |
| 05/25/2001 | WO2001036977A2 Identification of disease markers involving mass-based-separation |
| 05/25/2001 | WO2001036684A2 Mammalian toxicological response markers |
| 05/25/2001 | WO2001036656A2 A complex between hyaluronic acid and a biomolecule and its use |
| 05/25/2001 | WO2001036646A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | WO2001036645A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036644A2 Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same |
| 05/25/2001 | WO2001036640A2 Human fgf-21 gene and gene expression products |
| 05/25/2001 | WO2001036638A2 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036636A2 Human notch ligand proteins and polynucleotides encoding the same |
| 05/25/2001 | WO2001036635A2 Neurite outgrowth-promoting factor homologue and nucleic acids encoding same |
| 05/25/2001 | WO2001036633A1 Novel protein and dna thereof |
| 05/25/2001 | WO2001036630A2 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 05/25/2001 | WO2001036629A1 Transfer compounds, the production and the use thereof |
| 05/25/2001 | WO2001036628A1 Methods of reversing drug resistance in cancer cells |
| 05/25/2001 | WO2001036626A2 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/25/2001 | WO2001036625A2 ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS |
| 05/25/2001 | WO2001036624A1 High order nucleic acid based structures |
| 05/25/2001 | WO2001036611A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036609A1 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036608A1 Reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036602A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| 05/25/2001 | WO2001036600A1 MOUSE ASPARTIC SECRETASE-2 (mASP-2) |
| 05/25/2001 | WO2001036594A1 Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT |
| 05/25/2001 | WO2001036588A2 Fusion proteins that specifically inhibit protein synthesis in neuronal cells |
| 05/25/2001 | WO2001036489A2 Erythropoietin forms with improved properties |
| 05/25/2001 | WO2001036486A2 Scfv antibodies against disease associated molecules |
| 05/25/2001 | WO2001036484A1 New olfactory receptor polypeptides and dna sequences thereof |
| 05/25/2001 | WO2001036483A1 Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders |
| 05/25/2001 | WO2001036479A1 G-protein coupled receptor |
| 05/25/2001 | WO2001036478A2 Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides |
| 05/25/2001 | WO2001036477A2 Inhibition of abc transporters by transmembrane domain analogs |
| 05/25/2001 | WO2001036476A2 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 05/25/2001 | WO2001036475A2 Biglycan and related therapeutics and methods of use |
| 05/25/2001 | WO2001036472A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001036470A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 05/25/2001 | WO2001036467A2 Mammalian receptor proteins; related reagents and methods |
| 05/25/2001 | WO2001036462A2 Protein c derivatives |
| 05/25/2001 | WO2001036461A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001036457A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/25/2001 | WO2001036456A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036452A2 Heteroclitic analogs of class i epitodes |
| 05/25/2001 | WO2001036451A1 Vitamin e derivatives |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001036448A2 Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions |
| 05/25/2001 | WO2001036446A2 Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases |
| 05/25/2001 | WO2001036445A1 Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
| 05/25/2001 | WO2001036443A1 Antisense modulation of nck-2 expression |
| 05/25/2001 | WO2001036441A1 Antisense modulation of src-3 expression |
| 05/25/2001 | WO2001036440A1 23 human secreted proteins |
| 05/25/2001 | WO2001036432A2 18 human secreted proteins |
| 05/25/2001 | WO2001036419A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 05/25/2001 | WO2001036039A2 Iontophoretic transdermal delivery of peptides |
| 05/25/2001 | WO2001036001A2 Interferon gamma conjugates |
| 05/25/2001 | WO2001035998A1 Compositions for transdermal and transmucosal administration of therapeutic agents |
| 05/25/2001 | WO2001035993A2 Compositions and methods for stimulating an immune response against infectious agents |
| 05/25/2001 | WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 05/25/2001 | WO2001035987A1 An aqueous solution formulation of alpha-interferon |
| 05/25/2001 | WO2001035986A2 Methods and compositions for modulating er-stress-induced cholesterol accumulation |
| 05/25/2001 | WO2001035985A1 P-superfamily conopeptides |
| 05/25/2001 | WO2001035984A1 Use of peptide |
| 05/25/2001 | WO2001035983A1 Pharmaceutical composition for treatment of diarrhea |
| 05/25/2001 | WO2001035982A1 Antiinflammatory medicinal compositions |
| 05/25/2001 | WO2001035981A1 Methods and compositions for treatment of disease |
| 05/25/2001 | WO2001035977A2 Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes |
| 05/25/2001 | WO2001035976A1 Treatment or prevention of photoaging and skin cancer |
| 05/25/2001 | WO2001035975A2 Treatment of subnormal bone mineral density |
| 05/25/2001 | WO2001035974A2 Aplidine treatment of cancers |
| 05/25/2001 | WO2001035970A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035953A2 Exercise and muscle enhancement formulations |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035914A1 Use of nonimmunosuppressive cyclosporin derivatives for hair growth |
| 05/25/2001 | WO2001035903A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001035901A2 Use of enzymes for skin expansion |
| 05/25/2001 | WO2001035899A2 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 05/25/2001 | WO2001035810A2 Cancer immunotherapy and diagnosis using cytochrome p450 1b1 |
| 05/25/2001 | WO2001035732A1 An animal model for studying hormone signalling and method of modulating the signalling |
| 05/25/2001 | WO2001018039A3 INCREASED PRODUCTION OF INTERFERON-$g(a) |
| 05/25/2001 | WO2001011085A3 Bdnf polymorphism and association with bipolar disorder |